AI Market Mood: Stock Dashboard
HRTX
Fundamental
Company: Heron Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.12
Insider Own: 1.57%
Shs Outstand: 188.31M
Perf Week: -11.75%
Market Cap: 144.13M
Forward P/E: 5.88
EPS next Y: 0.13
Insider Trans: 0.00%
Shs Float: 185.57M
Perf Month: -35.76%
Enterprise Value: 239.19M
PEG: -
EPS next Q: -0.01
Inst Own: 82.45%
Short Float: 19.84%
Perf Quarter: -41.19%
Income: -20.20M
P/S: 0.93
EPS this Y: 83.33%
Inst Trans: -0.59%
Short Ratio: 21.59
Perf Half Y: -41.19%
Sales: 154.90M
P/B: 10.84
EPS next Y Percentage: 750.00%
ROA: -4.47%
Short Interest: 36.83M
Perf YTD: -41.19%
Book/sh: 0.07
P/C: 3.09
EPS next 5Y: -
ROE: -
52W High: 2.61 -70.71%
Perf Year: -68.54%
Cash/sh: 0.25
P/FCF: -
EPS past 3/5Y: 58.31% 45.44%
ROIC: -13.03%
52W Low: 0.76 -0.07%
Perf 3Y: -59.87%
Dividend Est.: -
EV/EBITDA: 854.26
Sales past 3/5Y: 12.89% 11.81%
Gross Margin: 73.31%
Volatility W: 8.20%
Volatility M: 8.94%
Perf 5Y: -94.72%
Dividend TTM: -
EV/Sales: 1.54
EPS Y/Y TTM: -30.68%
Oper. Margin: -1.32%
ATR (14): 0.08
Perf 10Y: -95.32%
Dividend Ex-Date: -
Quick Ratio: 1.51
Sales Y/Y TTM: 7.36%
Profit Margin: -13.04%
RSI (14): 24.06
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 2.48
EPS Q/Q: -165.69%
SMA20: -21.45%
Beta: 1.41
Target Price: 4.33
Payout: -
Debt/Eq: 9.81
Sales Q/Q: -0.47%
SMA50: -35.32%
Rel Volume: 0.88
Prev Close: 0.80
Employees: 128
LT Debt/Eq: 9.81
Earnings: Feb 26 BMO
SMA200: -45.46%
Avg Volume: 1.71M
Price: 0.76
IPO: Aug 26, 1987
Option/Short: Yes / Yes
EPS/Sales Surpr.: 0.00% 1.81%
Trades:
Volume: 1,505,971
Change: -4.39%
Technical:
Latest News:
Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital ... somewhat bullish
HRTX
Summary: Capital One Financial initiated coverage on Heron Therapeutics with an overweight rating and a $6.00 price target. Other research analysts have also issued positive ratings for the company. Heron Therapeutics recently reported better-than-expected quarterly earnings. Institutional investors have shown interest in the company.
Full article2024-04-24T18:45:09Z
Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendation very bullish
HRTX
Summary: Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with an Overweight recommendation and a projected 175.68% upside in the stock price. Multiple institutional investors hold significant amounts of shares in Heron Therapeutics.
Full article2024-04-24T00:06:43Z